Skeletal muscle atrophy during aging, a process known as sarcopenia, is associated with muscle weakness, frailty, and the loss of independence in older adults. The mechanisms contributing to sarcopenia are not totally understood, but muscle fiber loss due to apoptosis, reduced stimulation of anabolic pathways, activation of catabolic pathways, denervation, and altered metabolism have been observed in muscle from old rodents and humans. OBJECTIVE: Recently, histone deacetylases (HDACs) have been implicated in muscle atrophy and dysfunction due to denervation, muscular dystrophy, and disuse, and HDACs play key roles in regulating metabolism in skeletal muscle. In this review, we will discuss the role of HDACs in muscle atrophy and the potential of HDAC inhibitors for the treatment of sarcopenia. CONCLUSIONS: Several HDAC isoforms are potential targets for intervention in sarcopenia. Inhibition of HDAC1 prevents muscle atrophy due to nutrient deprivation. HDAC3 regulates metabolism in skeletal muscle and may inhibit oxidative metabolism during aging. HDAC4 and HDAC5 have been implicated in muscle atrophy due to denervation, a process implicated in sarcopenia. HDAC inhibitors are already in use in the clinic, and there is promise in targeting HDACs for the treatment of sarcopenia.
Introduction
The age-related loss of muscle mass, or sarcopenia, is a debilitating condition affecting older adults. Sarcopenia is a major contributor to frailty and is associated with a number of co-morbidities, including bone loss, infection, and metabolic disease, and can lead to falls and placement in nursing homes [1, 2] . Muscle strength is inversely correlated with all-cause mortality in men and women, suggesting sarcopenia is a biomarker for health in older adults [3] [4] [5] [6] . Sarcopenia is characterized by molecular, histological, and functional alterations to skeletal muscle, peripheral nerves, and neuromuscular junc-tions [7] . While the causes of these changes are not fully understood, potential mechanisms include lifestyle factors, like lack of exercise, or pathologies, like denervation and altered metabolism. No pharmaceutical treatments exist for sarcopenia, and the only generally accepted intervention is physical exercise and resistance training, which can induce muscle hypertrophy in elderly men and women [8] [9] [10] . Furthermore, hormonal therapy and nutritional supplements are currently under investigation. This review will discuss the emerging role of histone deacetylases (HDACs) in skeletal muscle disease and the implications for the treatment of sarcopenia.
Sarcopenia
The loss of muscle mass is relatively constant during aging; approximately 1% of lean mass is lost each year after age 50 [11, 12] . Muscle strength declines at approximately three times this rate [13] , suggesting the loss of muscle mass is not the only contributing factor to weakness during aging, and other factors, including peripheral nerve and excitation-contraction dysfunction and inflammation, may contribute to the loss of strength during aging. Some researchers use the term "dynapenia" to describe the loss of strength with age [14] , and in fact strength may be more important for the maintenance of healthspan during aging. In this review, we will use the term "sarcopenia" to describe the various pathologies associated with skeletal muscle during aging, including atrophy, reduced strength, metabolic changes, inflammation, stem cell dysfunction, and denervation, as HDACs have potential roles in many of these processes. Sarcopenia is not technically a disease according to the International Classification of Diseases and is poorly defined in the clinic (one definition is muscle weakness two standard deviations from the average of a young reference group [15] , and another definition by the European Working Group on Sarcopenia in Older People defines sarcopenia as low muscle mass with poor function, as set by age-and gender-specific standards [16] ). The lack of a clinical definition of sarcopenia has hampered sarcopenia research and the development of treatments for sarcopenia.
Sarcopenia can be defined using muscle mass, muscle strength, or other performance measurements, and the prevalence of sarcopenia depends on the method for determining muscle mass or performance and the population examined. In one study, sarcopenia was estimated to affect approximately 23% of women and 27% of men aged 64-92 years of age [17] . In a longitudinal study, loss of muscle mass and strength was greater in men than in women [18] . The percent of sarcopenic individuals clearly increases in the eighth and ninth decade of life [19, 20] ; muscle performance in 80 year olds is approximately half that of peak performance [21] . Elimination of sarcopenia would have enormous social and economic benefits. Sarcopenia is a major factor in the functional decline and disability due to aging, and most frail older adults are also sarcopenic [16] . Care for frail individuals is difficult because of the number of systems affected and increased social needs, and care often falls to family members and institutions. In 2000, sarcopenia was estimated to account for $18.5 billion in healthcare costs in the United States [22] , and a 10% reduction in the incidence of sarcopenia would save the U.S. economy $1.1 billion according to a paper published in 2004 [23] . This number has undoubtedly risen in the decade since, and healthcare costs due to sarcopenia will continue to rise as the proportion of people over the age of 65 increases in the United States.
It is not known what causes sarcopenia, although a number of mechanisms have been proposed. The loss of muscle mass could be due to lifestyle factors like the lack of exercise or nutritional deficiencies, i.e. low protein or vitamin D intake [24] . A single serving of protein does increase protein synthesis in older adults [25, 26] ; however, it is not clear if protein supplementation prevents sarcopenia, and even active adults experience muscle loss during aging [27] [28] [29] . Additionally, genetics contribute to muscle strength and likely plays a role in sarcopenia. Genetic factors account for 30%-85% of the variance in muscle strength, depending on the group studied and endpoints measured [30] [31] [32] . While genetic factors also contribute to the age-related decline in muscle strength [33, 34] , the genetic contributions to muscle strength declines during aging, with the effects of environment becoming more important to muscle strength in older adults [35] .
Muscle strength [4, 6, 36] and mass [37] correlate with all-cause mortality, suggesting that basic aging processes are an underlying cause of sarcopenia. Several signaling pathways related to aging have also been implicated in muscle atrophy, including growth hormone and insulin-like growth factor signaling through mTOR (mammalian target of rapamycin), Akt (protein kinase B), and FOXO (Forkhead box O) and inflammatory signaling through NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells) and TNF-␣ (tumor necrosis factor alpha) [38] [39] [40] [41] [42] [43] [44] [45] [46] . Alterations in these signaling pathways can lead to activation of the major degradation processes, including the ubiquitin proteasome system, autophagy, necrosis, and apoptosis, or the inhibition of protein synthesis, potentially causing muscle atrophy, although the effect of aging on these processes in skeletal muscle is complex [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . There are conflicting reports on the effect of age on stem cell numbers, but the regenerative capacity of muscle stem cells is clearly reduced in older adults and aged mice compared to young controls, which is at least partly due to the aged niche and altered expression of myogenic regulatory transcription factors [57] [58] [59] [60] [61] [62] . Transplantation of stem cells from aged mice rejuvenated ex vivo can restore function to muscle in aged mice, although depletion of stem cells during aging does not lead to sarcopenia per se [63, 64] . Thus, pathogenic processes like the imbalance between protein synthesis and protein degradation, endocrine dysfunction, denervation, loss of muscle fibers by apoptosis, stem cells dysfunction, and altered metabolism are possible mechanisms that cause sarcopenia.
Histone deacetylases
Chromatin is a highly organized complex of DNA and histone proteins, and its structure is associated with transcriptional activity. Tightly packaged chromatin, or heterochromatin, is associated with repression of transcriptional activity, and open chromatin, or euchromatin, is associated with transcriptional activation. The nucleosome is the basic unit of chromatin and is formed from DNA and four histone proteins: 146 base pairs of DNA circumscribe an octamer composed of two copies each of histone H3 and histone H4 and two copies of the histone H2A/H2B dimer. Each histone has an N-terminal tail that protrudes from the nucleosome and is subject to a number of post-translational modifications, including acetylation, methylation, ubiquitination, and phosphorylation. These post-translational modifications are responsible for recruiting DNA binding proteins and can affect histone-DNA interactions. Acetylation is a well-described histone modification that masks the positive charge of lysine, reducing the attraction between negatively charged DNA and positively charged histones. Thus, increased levels of histone acetylation are associated with euchromatin and increased transcriptional activity [65] . At the same time, bromodomain-containing proteins can bind acetyllysine modifications and can activate or inhibit transcription [66] . Protein acetylation is regulated by acetyl-CoA availability and cellular pH in addition to enzymatic regulation [67] .
Protein acetylation is regulated by two classes of enzymes: histone acetyltransferases (HATs) and HDACs. These enzymes are also called to lysine acetyltransferases and lysine deacetylases, reflecting the fact that several thousand non-histone proteins are acetylated, including the majority of metabolic enzymes as well as muscle contractile proteins, including several myosin heavy chain proteins, tropomyosin 2, and nebulin [68] . Histone acetyltransferases are broadly divided into three families: GCN5-related acetyltransferases, the MYST [MOZ (monocytic leukemia zinc finger), Ybf2, Sas2 (something about silencing 2), and Tip60 (Tat interactive protein, 60 kDa)] family, and the p300/CBP [cAMP response element-binding protein (CREB) binding protein] family. Mammalian HDACs are divided into four classes based on homology to Saccharomyces cerevisiae HDACs [69] . Class I HDACs include HDAC1-3 and HDAC8 and are related to yeast rpd3 (reduced potassium dependency 3); class II HDACs include HDAC4-7 and HDAC9-10 and are related to yeast hda1 (histone deacetylase 1); class III HDACs are the NAD + (nicotinamide adenine dinucleotide)-dependent sirtuins, Sirt1-7 (silent mating type information regulation 2 homolog 1-7), and are related to yeast sir2 (silent information regulator 2); HDAC11 is the sole member of class IV. Eukaryotic species typically have representative but a varying number of members from each class. Sirtuins are extensively studied in the field of aging, and their role in muscle atrophy has been reviewed elsewhere [70, 71] . Sirtuin activation is associated with improved metabolism in skeletal muscle during aging. For example, Sirt1 activates PGC-1␣ (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) [72] , which is known to protect against sarcopenia [56] , and supplementation with the sirtuin cofactor NAD + protects against agerelated metabolic changes in skeletal muscle in a Sirt1-dependent manner [73] . While Sirt1 inhibits myoblast differentiation [74] , it is not known if this is relevant to muscle stem cell dysfunction during aging. This review will focus on the class I and II HDACs and their potential as targets for interventions in sarcopenia.
Class I, II, and IV HDACs catalyze the Zn 2+ -dependent hydrolysis of acetyllysine to lysine and acetate. These classical HDACs are emerging targets for metabolic disease [75] , cancer [76] , and neurodegeneration [77] . Class I HDACs are ubiquitously expressed and localized in the nucleus and are found in transcriptional corepressor complexes with Sin3 (switch independent transcription regulator family member A), NuRD (nucleosome-remodeling complex), and CoREST (repressor element-1 silencing transcription factor corepressor 1) [78] . These enzymes inhibit many transcription factors, including Sp1 (specificity protein 1), p53, and retinoblastoma protein. Class II HDACs are further subdivided into class IIa and class IIb. Class IIa HDACs shuttle between the nucleus and cytoplasm and are involved in signal transduction pathways [78] . Class IIa HDACs are phosphorylated by a number of kinases, including protein kinase D1 (PKD) [79] , protein kinase C [80] , salt inducible kinase 1 (SIK1) [81] , AMP-activated protein kinase (AMPK) [82] , and calcium/calmodulin-dependent kinase II (CaMK II) [83] , in the nucleus, resulting in the exposure of a nuclear export signal, binding by 14-3-3 proteins, and export from the nucleus. The class IIb HDAC6 and HDAC10 are mostly cytoplasmic and acetylate tubulin and proteins involved in autophagy [84] . Little is known about HDAC11, the sole class IV HDAC.
The role of histone deacetylases in skeletal muscle development and maintenance

Histone deacetylases in muscle development
Skeletal muscle is formed by the differentiation and fusion of muscle precursor cells. During this process, the expression of hundreds of genes is altered, including muscle structural and remodeling genes. HDACs have emerged as crucial regulators of muscle development, and this topic has been reviewed extensively elsewhere [85] and will only be briefly discussed in this review. Myogenesis is coordinated by a family of basic helix-loop-helix (bHLH) transcription factors that include myoblast determination protein (MyoD), myogenic factor 5 (Myf-5), and myogenin, which are regulated by class I and class II HDACs. The activity of these bHLH transcription factors is enhanced by myocyte enhancer factor 2 (MEF2), which is in turn regulated by the class IIa HDACs. The class IIa HDACs, namely HDAC4, HDAC5, HDAC7, and HDAC9, have been implicated in myogenesis via the regulation of MEF2 [86] [87] [88] . These HDACs interact with MEF2 [89] and inhibit the differentiation of myoblasts [90, 91] . While class IIa HDACs repress MEF2, this repression is independent of the deacetylase domain, suggesting that the effects of HDACs are due to the recruitment of other co-repressors or exclusion of transcriptional activators. In addition, the class I HDAC HDAC1 regulates the activity of MyoD and inhibits myoblast differentiation [92, 93] .
The inhibition of muscle differentiation by HDACs can be overcome by histone acetyltransferases or pharmacological HDAC inhibitors. The HATs p300 and glucocorticoid receptor interacting protein can displace HDACs bound to MEF2 and activate myoblast differentiation [94, 95] . Similarly, the HATs p300/CBP and p300/CBP-associated factor (PCAF) regulate MyoD-induced gene transcription [96] . Pharmacological inhibition of HDACs can similarly modulate myoblast differentiation, which is induced by low-serum conditions. When HDAC inhibitors are included in low-serum differentiation media, primary human myoblasts and rodent the C2C12 myoblast cell line are unable to differentiate. However, differentiation is enhanced in myoblasts treated with HDAC inhibitors while they are in growth media and prior to the induction of differentiation [97] . The roles of HDACs in muscle stem cells in mature animals are not as well defined. Aging affects muscle stem cell differentiation and proliferation [reviewed in [98] ], which are key processes regulated by HDACs, suggesting that HDAC inhibitors may have therapeutic use in regenerative therapies for sarcopenia.
Histone deacetylases in neurogenic muscle atrophy
Neurogenic muscle atrophy results from the death and dysfunction of motor neurons or alterations of neuronal transmission at the synapse between the motor neuron and muscle fiber, which is called the neuromuscular junction. This form of muscle atrophy can result from peripheral nerve injury, toxins that affect motor neurons, and inherited and acquired diseases like amyotrophic lateral sclerosis and Lambert-Eaton syndrome. HDAC4 is specifically upregulated in animal models and human diseases resulting from neurogenic muscle atrophy [99] . HDAC4 and HDAC5 regulate the transcription factor myogenin to execute the muscle atrophy program after loss of innervation by motor neurons [100] . In response to denervation, HDAC4 travels from the neuromuscular junction to the nucleus and activates myogenin, leading to the activation of the ubiquitin-proteasome system. Phosphorylation of HDAC4 leads to the exposure of a nuclear export sequence, binding of HDAC4 to a 14-3-3 protein, and export from the nucleus [101] . Mice lacking HDAC4 or HDAC5 are protected from muscle atrophy in response to denervation [100] . These class IIa HDACs repress Dach2 (dachshund homolog 2), which negatively regulates myogenindependent activation of the ubiquitin-proteasome system, including the E3 ligases muscle-specific RING finger-1 (MuRF1) and atrogin-1 [100] .
Another key mediator of denervation-induced muscle atrophy is FOXO3a, whose activity is regulated by acetylation. Increasing acetylation of FOXO3a by activating HATs and inhibiting HDACs inhibits its transcriptional activity and can protect against muscle atrophy due to denervation [102] . HDACs are extensively regulate and are regulated by microRNAs during denervation and other skeletal muscle diseases [103] [104] [105] [106] [107] , adding another layer of complexity and therapeutic option for targeting HDACs in sarcopenia. Inhibitors of HDACs have shown promise in several preclinical models of neurogenic muscle atrophy, including amyotrophic lateral sclerosis [108] , spinal muscular atrophy [109] [110] [111] , and peripheral nerve injury [112] .
Histone deacetylases in metabolism and exercise
Muscle atrophy due to denervation is associated with changes in skeletal muscle fiber type. Following motor neuron death and denervation, motor neurons adjacent to the denervated muscle fiber re-innervate by axonal sprouting. Because muscle fiber type is determined by motor neuron innervation, this cycle of denervation and re-innervation results in grouping of muscle fibers of the same fiber type. Class IIa HDACs and MEF2 regulate this specification of muscle fiber type. In type I fibers, HDAC4 is selectively degraded, resulting in activation of genes involved in oxidative metabolism and the formation of type I oxidative fibers [113] . Overexpression of HDAC4 also enhances glycolysis in skeletal muscle and is required for the reduction in glycolytic enzymes that occur after denervation [114] . Defects in oxidative metabolism are also observed when HDAC5 is not responsive to phosphorylation [115] , suggesting that inhibition of HDACs could increase oxidative metabolism in skeletal muscle.
HDACs also play a role in the metabolic adaptations that occur during exercise. After 60 minutes of cycling, histone acetylation is increased at histone H3 lysine 36 in skeletal muscle, which is associated with transcriptional activation [116] . This change is associated with the phosphorylation HDAC4 and HDAC5 by PKD and their export from the nucleus, resulting in elevated MEF2 activity and increased expression of glucose transporter type 4 (GLUT4) [82, 115, 116] . Another class IIa HDAC kinase, AMPK, is known to activate the expression of GLUT4 in skeletal muscle by phosphorylating HDAC5 [82] . The class I HDACs also play a critical role in skeletal muscle metabolism. Mice lacking both HDAC1 and HDAC2 experience a myopathy characterized by muscle degeneration, mitochondrial dysfunction, inhibition of autophagy, and increased oxidative metabolism [117] . In this regard, there is a clear difference between the total loss of HDACs, as occurs in genetic models, and pharmacological inhibitors of HDACs, which only reduce activity and maintain the key ability of HDACs to form complexes with other proteins. Pharmacological inhibitors of HDACs increase the expression of GLUT4 in skeletal muscle [118] , and HDAC inhibitors have shown promise in models of obesity and diabetes, preventing insulin resistance and reducing circulating triglycerides and cholesterol [119, 120] , although these effects may be due to the roles of HDACs in liver and adipose tissue [121] [122] [123] .
Histone deacetylases in muscular dystrophy
Muscular dystrophies are a group of skeletal muscle diseases characterized by muscle wasting and weakness. The prototypical muscular dystrophy, Duchenne muscular dystrophy, is caused by mutations in the dystrophin gene, which encodes a structural protein that connects the muscle cytoskeleton with the extracellular matrix. HDAC2 is elevated in muscle from dystrophin-deficient (MDX) mice, and class-I-specific HDAC inhibitors and siRNA targeting HDAC2 are protective in MDX mice [124] . Increased activity of CREB in skeletal muscle leads to a condition resembling muscular dystrophy, and expression of the class II HDAC kinase SIK1 prevents this dysfunction [81] , suggesting class II HDACs may also play a role in muscular dystrophy. HDAC inhibitors improve morphological and functional deficits in MDX mice, including increasing muscle fiber size and reducing fibrosis and inflammation [125, 126] . HDAC inhibitors increase muscle fiber size through the production of follistatin, an antagonist of myostatin [97] . Myostatin is a member of the TGF-␤ (transforming growth factor beta) family that, when mutated, results in muscular individuals. The ability of HDAC inhibitors to reduce fibrosis in models of muscular dystrophy has been linked to effects on fibro/adipogenic progenitors (FAPs) residing in skeletal muscle. In diseased conditions, FAPs contribute to the formation of intramuscular fat and fibrosis. However, FAPs are also able to promote muscle regeneration by enhancing muscle stem cell differentiation [127] and increasing clearance of damaged muscle debris [128] . In mouse models of muscular dystrophy, HDAC inhibitors enhance the ability of FAPs to stimulate muscle stem cells during early stages of the disease [129] .
Histone deacetylases in muscle atrophy due to disuse and poor nutrition
Similar to denervation-induced muscle atrophy, myogenin is activated in skeletal muscle in response to fasting or nutrient deprivation, but under these conditions HDAC1 activates myogenin. Reduction in the level of HDAC1 or inhibition of its activity prevents muscle atrophy after nutrient deprivation [130] . The non-specific HDAC inhibitor trichostatin A (TSA) prevents muscle atrophy in a rodent model of disuse atrophy [131] . TSA reduces oxidative stress and prevents the expression of MuRF1 after hindlimb unloading in rodents. This effect was found to be due to the inhibition of HDAC1 using class-specific HDAC inhibitors [130] . In a cast immobilization model of disuse atrophy, class I HDAC inhibitors prevented muscle atrophy and the expression of ubiquitin-proteasomal and autophagic genes, while class II HDAC inhibitors had no effect. HDAC1 was subsequently identified as cause of muscle atrophy in these models using dominant-negative HDAC variants [130] . These studies demonstrate the power of pharmacological and genetic manipulation of HDACs to uncover the isoforms that contribute to specific skeletal muscle diseases.
Potential role of histone deacetylases in sarcopenia
One potential contributor to sarcopenia is deterioration of the motor unit [132] , which is a motor neuron and all the muscle fibers it innervates and the neuromuscular junction. Loss of motor neuron activity and alterations at neuromuscular junctions are key events in the loss of muscle mass during aging [133] [134] [135] [136] , even though motor neuron numbers in the spinal cord do not decline with age in mice [137] . We found that HDAC4 is elevated in muscle from old mice, consistent with a role of denervation in sarcopenia [138] . Even though denervation is apparent at 26 months of age in C57Bl/6 mice, we did not observe phosphorylated HDAC4 in skeletal muscle from old mice. Thus, similar to studies on muscular dystrophy [81] and metabolism [82] , targeting class II HDAC kinases is a promising approach that may avoid the potential side effects of a nonspecific HDAC inhibitor. Another result of the cycle of denervation and reinnervation is the increase in size of the motor unit [139] and reduced acetylcholine receptor numbers and firing release [140] , and these effects are likely a major contributor to the loss of muscle strength during aging. Regression analysis revealed that only 13% of the variation in muscle strength is explained by muscle mass in older adults [141] and that muscle fiber cross sectional area has a similarly small correlation with strength [142] , suggesting that other factors, like innervation by motor neurons, are critical for the loss of strength during aging [143] . Thus, further research is needed on the role of HDACs in motor neurons and neuromuscular junctions.
Muscle from sarcopenic individuals and patients with muscular dystrophy share some phenotypes, including increased fibrosis and neuromuscular junction fragmentation [144] . However, the decline in motor units observed during sarcopenia is not seen in muscular dystrophy, and there are no reports of alterations in the dystrophin-associated protein complex during aging. Thus, there is little evidence that sarcopenia is a form a muscular dystrophy. However, studies on HDACs and muscular dystrophy demonstrate an important principle for the potential role of HDACs in sarcopenia; namely, that specific HDAC isoforms are implicated in different diseases of skeletal muscle. Further research is needed using targeted genetic and pharmacological approaches to determine if specific HDAC isoforms contribute to sarcopenia.
We and others have shown a loss of structural and physiological integrity in motor neurons and at neuromuscular junctions during aging and have implicated oxidative stress in these processes [137, [145] [146] [147] . We recently showed that the HDAC inhibitor butyrate reduces oxidative damage and increases antioxidant activity in muscle from old mice [138] . A compound related to butyrate, the ketone body beta-hydroxybutyrate, is an endogenous histone deacetylases inhibitor that is upregulated by dietary restriction and protects against oxidative stress in mice [148] . Beta-hydroxybutyrate and another HDAC inhibitor, TSA, extend lifespan in Caenorhabditis elegans, and RNA interference of two C. elegans HDAC genes also increases lifespan [149, 150] . These effects likely occur through dietary restriction mechanisms [149, 150] , suggesting that dietary restriction and HDAC inhibitors function through similar mechanisms. Together with data demonstrating that deletion of the model class I HDAC rpd3 extends lifespan in S. cerevisiae [151] and that HDAC inhibitors increase lifespan in Drosophila [152] , it is possible that HDACs play a role in general aging processes. Fig. 1 . Potential roles of histone deacetylases in sarcopenia. Histone deacetylases (HDACs) regulate critical muscle-specific transcription factors (blue). Different HDAC isoforms (green) can affect the differentiation process, which is regulated by MyoD and other transcription factors, suggesting that HDACs may play a role in age-related changes in satellite cells. HDAC4 and HDAC5 activate myogenin-dependent gene transcription, which includes the ubiquitin proteolytic machinery, that may contribute to muscle atrophy during aging. HDACs also regulate Mef2, which regulates metabolic processes known to change during aging. HDAC inhibitors have potentially beneficial effects in skeletal muscle, including the upregulation of antioxidant enzymes and the increase of follistatin, which inhibits myostatin. HDACs can be inhibited pharmacologically with HDAC inhibitors, including trichostatin A and butyrate, and multiple signaling pathways converge on class II HDACs, resulting in their phosphorylation by kinases (orange) and transport out of the nucleus by 14-3-3 proteins (yellow).
Class IIa HDACs activate glycolysis in skeletal muscle [114, 115] , and HDAC3, a class I HDAC, inhibits mitochondrial biogenesis [153] . Interestingly, dietary restriction, which preserves muscle mass during aging [154, 155] , prevents the decline in oxidative metabolism in skeletal muscle from old mice [156] , suggesting that dietary restriction might modulate histone deacetylases during aging. Shifts in body composition during aging may also contribute to sarcopenia, as fat mass is inversely correlated with muscle strength and mobility in the elderly [22, [157] [158] [159] . This may be due to deposition of fat in skeletal muscle during aging, which is associated with insulin resistance and low muscle strength in older adults [13, 160] . HDAC inhibitors increase oxidative metabolism and reduce intramuscular fat during aging, which may explain improvements in metabolism in old mice [138] .
An imbalance between protein synthesis and degradation can result in muscle growth or atrophy, and sarcopenia may result from increased protein degradation [53, 161] . HDACs are critical mediators of catabolic pathways, including ubiquitinproteasomal degradation and autophagy. Although a number of studies have investigated these pathways, it is still not clear if catabolism is increased during aging [50, [52] [53] [54] [55] [56] 162] . Reduced protein synthesis might also contribute to the net reduction in protein levels during aging. Mitochondrial protein synthesis rates are reduced by middle age, although no further decline is seen in the elderly [163] , even though a further loss of muscle mass is reported. Another study found similar results with whole body protein synthesis rates as well as myosin heavy chain synthesis in skeletal muscle [164] . Importantly, the elderly are able to increase protein synthesis rates in response to amino acid intake [25] . Whether HDACs affect protein synthesis is an outstanding question.
Although the role of muscle stem cells in the development of sarcopenia has recently been called into question [63] , stem cells remain a promising therapy for sarcopenia, but we need to know more about the role of HDACs in muscle stem cells in vivo to determine if HDAC inhibitors might play a role in regenerative therapies for sarcopenia. Similarly, while HDAC inhibitors inhibit myostatin by increasing follistatin, there is not a clear role for myostatin in the development of sarcopenia [165] . However, myostatin is a promising target for intervention [166] and is under investigation by a number of pharmaceutical companies for the treatment of sarcopenia and other skeletal muscle diseases [167] .
Conclusions and future directions
Many challenges remain for the development of HDAC inhibitors and other pharmacological agents to treat sarcopenia. There is no universal method to diagnose sarcopenia in an individual patient, and it is not clear what endpoints are most relevant for clinical trials. Broad goals of restoring function and preventing dependent living need to be distilled into clinically measurable endpoints like mortality and hospitalization rate. It is an exciting time for sarcopenia research, as new targets for intervention have recently been identified in rodent models, including the cytokine TWEAK (tumor necrosis factor-related weak inducer of apoptosis) [168, 169] , TGF-beta inhibitors [170] , activin [171] , sirtuins [70] , angiotensin receptors [172] , GDF11 (growth differentiation factor 11) [173] [174] [175] , NAD + [176] , and ATF4 (activating transcription factor 4) [177] , along with continued research on myostatin [178] , PGC-1␣ [56] , and steroids [179] .
Studies on HDACs in models of denervation, exercise, metabolism, muscular dystrophy, and disuse atrophy have given us a better understanding of the potential mechanisms underlying sarcopenia and may lead to successful intervention in sarcopenia (see Fig. 1 ). Further research is needed to determine if specific isoforms contribute to sarcopenia and the mechanisms by which HDAC inhibitors act to prevent muscle loss. Although the expression of most HDACs has not been reported to change during aging, HDACs function throughout the genome and affect non-histone protein function. Chromatin immunoprecipitation followed by DNA sequencing and analysis of the acetylome during aging may uncover additional HDAC-related targets for intervention in sarcopenia. HDAC inhibitors are relatively well studied in cancer treatment, and several HDAC inhibitors are already approved by the U.S. Food and Drug Administration. The increasing interest in HDAC inhibitors has led to the development of class-specific inhibitors, with isoform-specific inhibitors currently under development, which will help researchers uncover the role of HDACs in sarcopenia. Based on the numerous beneficial effects of HDAC inhibitors in skeletal muscle under pathological conditions, we believe that HDAC inhibitors are promising therapeutics for the treatment of sarcopenia and potentially age-related metabolic disease.
